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Introduction 
Influenza, generally known as the flu, is one of the most 
common viral respiratory infections with the capacity to dis-
seminate around the world, one could say at lightning speed, 
in seasonal epidemics, reaching its summit over the course of 
winter. Influenza is a serious infectious disease caused by 
RNA viruses which belong to the Orthomyxoviridae family. 
The first influenza pandemic was documented in 1580 and it 
has remained a viral disease of global dimension ever since 1. 
The four researchers analyzed medical literature reported du-
ring the Spanish Flu pandemic from 1918 to 1920. The meta-
analysis of these data showed that treatment of new victims 
of the virus in 1918 with convalescent whole blood, plasma 
or serum collected from patients who had recovered from 
Spanish Influenza resulted in reduced case-fatality rate of 
severely ill patients by 50% 2. In 1931, Goodpasture was the 
first who discovered a viral growth in embryonated hen’s 
egg, and in the 1940s, the US military developed the first ap-
proved inactivated vaccines for influenza, used during World 
War II 1. Unlike other viral vaccines, annual influenza vacci-
nation is recommended due to fast evolution of influenza vi-
ruses, evolve one million times faster than mammals, which 
results in high mutation rates and antigenic variations known 
as antigenic drift, a minor change such as amino acid substi-
tution in virus surface proteins hemagglutinin (HA) and/or 
neuraminidase (NA), and antigenic shift, a new combination 
of different flu genes emerged to infect people 3–5.  
Traditional influenza vaccine composition  
There are three distinct types of influenza viruses, desig-
nated A, B, and C, with types A and B of influenza viruses be-
ing the major pathogens in humans. Influenza A can infect hu-
mans, birds, pigs and other species 6. Influenza B and C are 
primarily human pathogens. Unlike influenza A and B viruses, 
influenza C virus is of little clinical importance 7. The core of the 
A and B viruses is surrounded by a lipid in nature membrane, or 
‘envelope’ derived in part from modified host cell membranes, 
from which may protrude spikes, glycoprotein complexes, cor-
responding to the hemoglutinin (HA) trimer ligand and the neu-
raminidase (NA) tetramer ligand 8. HA surface protein enables 
the virus to get attached to sialic acid-containing receptors and 
viral entry by membrane fusion. NA surface protein is a recep-
tor-destroying enzyme responsible for viral release and cell-to-
cell spreading 9. There are 17 HA subtypes of influenza virus 
whereas 9 subtypes of NA are known to be present 10. Nowdays 
traditional flu vaccines (called “trivalent” vaccines), composed 
of two types of inactivated influenza viruses: an influenza A 
(H1N1) subtype virus, an influenza A (H3N2) subtype virus, 
and an influenza B virus, are used worldwide to protect from in-
fluenza and its serious complications 7. 
Influenza vaccination: Pros and cons 
A vaccine is a preparation of killed or inactivated mic-
robes (parasites, viruses, bacteria), or purified products deri-
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ved from them, used to elicit the immune system to a parti-
cular disease 11. Human vaccines are regarded as one of the 
safest medical products available, and the most effective 
method of prophylaxis we have against infectious diseases 
for the general population. Medical community considers 
current human vaccines also safe and effective for patients 
with autoimmune diseases 12, 13, but like any other medical 
product, there may be risks. In general, all inactivated virus 
vaccines are considered safe and effective11.  
Even though influenza infection per se has seldom been 
associated with various organ-specific and systemic autoim-
mune diseases, systemic and neurological autoimmune phe-
nomena have been reported following influenza vaccine that 
consists of inactivated purified surface fragments and no vi-
ral genetic material 14. In June 2009 the World Health Orga-
nization declared the new influenza of swine origin, A 
(H1N1), which originated in Mexico around March 18, 2009, 
was pandemic 15. A concern about pandemic influenza A 
(H1N1) 2009 vaccine was the possible occurrence of neu-
roimmunological adverse events, including Guillain-Barré 
syndrome (GBS). A causal relationship between the vaccine 
and this autoimmune neurological disease was suggested by 
the original Centers for Disease Control study during an out-
break of GBS in 1976 that was caused by the swine flu vac-
cine 16. A more than seven-fold increment in risk of GBS 
was observed when the influenza A (H1N1) subtype A/New 
Jersey/76 (A/NJ/76) vaccine had been applied in the United 
States in 1976. As a consequence, the vaccination campaign 
had to be suspended brusquely 17. In contrast to the A/NJ 
vaccine, in 1978-1979 introduction of a new HA type of in-
fluenza vaccine have failed to show a statistically significant 
excess risk of acquiring vaccine-related GBS 18. A retrospec-
tive epidemiological study done by Lasky et al. 19 on seaso-
nal influenza vaccines used in 1992–1993 and 1993–1994 
showed modest increases in risk of GBS. For the two seasons 
combined the risk of occurrence of GBS showed 95% confi-
dence interval (1.0, 2.8). The adjusted (age, sex, and vaccine 
season) relative risk of 1.7 (p = 0.04) suggested slightly more 
than one additional case of GBS within six weeks after vac-
cination in one million people. 
A population-based cohort study in Stockholm, Swe-
den, investigated over a period of 8–10 months, the risk of 
neurological and autoimmune disorders of special interest in 
people vaccinated against pandemic A (H1N1) with mono-
valent Pandemrix® (GlaxoSmithKline, Middlesex, UK) 2009 
vaccine compared with those who remained unvaccinated. 
The study population comprised 1.98 million people registe-
red in Stockholm county with more than one million people 
vaccinated and 900,000 unvaccinated. This retrospective co-
hort study was devised for the purpose of linking individua-
lized data on pandemic vaccinations to an inpatient and spe-
cialist database on healthcare utilization in Stockholm county 
for follow-up during and after the pandemic period. The ove-
rall relative risk for GBS, multiple sclerosis (MS), type 1 di-
abetes, or rheumatoid arthritis among vaccinated compared 
with unvaccinated people remained unchanged 20. 
Three major neurological manifestations of an autoim-
mune nature have been viewed in conjunction with vaccina-
tion: the GBS, MS and autism 21. Among autoimmune adver-
se events, GBS remains the most frequently reported influ-
enza vaccine adverse neurological autoimmune event. For 
that reason, and the issue around GBS in 1976 another pro-
spective multinational case-control study in Europe 22 with 
an objective to evaluate any association between GBS and 
adjuvanted pandemic influenza A (H1N1) 2009 vaccine was 
performed. The main outcome measure was a relative risk 
estimate for GBS after influenza vaccine. The point estimate 
showed no association between pandemic influenza vaccina-
tion and GBS, although the upper confidence limit was 2.7 
meaning a potential increase in risk up to 2.7-fold or three 
excess cases per one million vaccinated people. 
GBS is a transient, often preceded by a respiratory or 
gastrointestinal illness, acute polyneuropathy, in Europe 
mostly presents as acute inflammatory demyelinating 
polyradiculoneuropathy, characterized by areflexic 
symmetrical motor paresis with mild sensory disturbances 23. 
The infections per se are usually not enough for triggering 
autoimmune diseases. There are clearly other factors invol-
ved: genetic, immunological and hormonal 24. This is 
probably why the role of influenza vaccination as a trigger of 
GBS remains controversial 22. 
Hence, the GBS-vaccine link controversy continuous. 
Two recent studies from the United Kingdom identified in-
fluenza-like illness/upper respiratory tract infection as a 
strong risk factor. An increased risk of GBS was seen shortly 
thereafter, consistent with observations that GBS is often 
preceded by a respiratory illness. It is however difficult to 
associate GBS with influenza virus infection solely since ot-
her respiratory pathogens, that can present as influenza-like 
illness, are also at their height in the winter. This study found 
no causal association of GBS with influenza vaccine; in-
stead, it pointed out to increased risk of GBS after influenza-
like illness. Furthermore, this study suggests that influenza 
vaccine should protect against GBS and also finds equally 
valuable to make an overall risk-benefit assessment - the risk 
of such events due to pandemic influenza vs the degree of 
vaccine protection 25, 26. 
While the substance of epidemiologic evidence, evalu-
ated over the last 30 years, does not support the association 
between influenza vaccination and GBS, the Committee of 
the Institute of Medicine (2011) found that an association 
cannot be ruled out with confidence, particularly because the 
annual antigenic reformulation of the influenza vaccine va-
ries from year to year and the potential for risk of GBS also 
varies 27.  
Pathophysiological concepts of multiple sclerosis 
with respect to antigen presenting cells 
In general, MS is heterogeneous disorder of the central 
nervous system. Although the factors that contribute to its 
heterogeneity are still confounding, at the same time we are 
quite assured that we talk about a complex genetic trait that 
is influenced by environmental variables such as exposure to 
infections, climate etc. There is no doubt that cellular and 
humoral immune mechanisms are implicated in the pathoge-
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nesis of demyelinating autoimmune diseases in the CNS in 
humans and animal models 28, 29. Furthermore, pathophy-
siological studies suggest that MS results from an immuno-
logical attack on white matter in the CNS and consequent 
breakdown of the myelin around axons and the possibility of 
secondary axonal damage as well. Plaques, the pathological 
signature of MS, are small round areas of demyelination that 
may occur anywhere within the white matter. Depending on 
their stage of development the varying proportions of immu-
ne cells and immunoreactive substances can be detected 30.  
Antigen presenting cells (APCs) are necessary for the 
pathogenesis of murine models of MS 31,32. APCs are invol-
ved in multiple stages during MS pathology, thenceforth the 
growing interest in studying these cells. MS seems primarily 
to be a disease that involves an immune response to antigens 
presented by major histocompatibility complex (MHC) class 
II molecules. Perivascular macrophages are an abundant cell 
type in the CNS. This location enables them to encounter 
pathogens and assist in controlling innate and adaptive im-
mune responses in the CNS. They are especially plentiful in 
actively demyelinating lesions and are characterized by hig-
her levels of MHC class II and CD45 in both rodents and 
humans compared to microglia 33. Although microglia are 
thought to exert a detrimental role on the brain, their precise 
contribution to brain inflammatory demyelination is largely 
unknown 34. In humans MHC class II is expressed in MS le-
sions 35. Additionally, human astrocytes express MHC class 
II in vitro upon IFN-γ stimulation 36. Further, the accumula-
tion of dendritic cells (DCs) within the CNS 37–39 is evident, 
yet the mechanisms of recruitment of DCs to the CNS conti-
nue to be an area of ongoing research. These infiltrating DCs 
may seem to some of us excessive, given the fact that the 
CNS has resident APCs (microglia and astrocytes). DCs are 
of hematopoietic origin, they evolve from lymphoid and 
myeloid precursors, respectively. There are two main subsets 
of DCs: conventional DCs (cDCs) and plasmacytoid DCs 
(pDCs) 40. DCs, upon activation through either Toll-like re-
ceptor (TLR) signaling or encountering with antigen (Ag), 
travel from resident tissues or sites of inflammation to the 
lymph nodes (LN). Classically, T cell activation occurs in 
the LN where DCs migrate after Ag uptake in peripheral tis-
sues. In experimental autoimmune encephalomyelitis (EAE) 
model, naive T cells are first introduced to myelin antigens 
in the periphery 41. Irla et al. 42 proposed that MHCII expres-
sion by pDCs confers natural protection against EAE by sti-
mulating the selective expansion of myelin-Ag-specific natu-
ral regulatory T cells in secondary lymphoid tissues. In our 
previous study we suggested that pDCs might be the one to 
make a connection between mild clinical signs expressed in 
the myelin oligodendrocyte glycoprotein (MOG) variant of 
EAE-induced mice and the expression of MHC class II mo-
lecules in the secondary lymphoid organs 43. Activation of 
DCs leads to their maturation, that is, upgrades the expres-
sion of MHC class II as well as co-stimulatory molecules 
(CD80, CD86, CD40). This way DCs become more efficient 
at presenting cognate Ag to naive as well as memory T cells, 
which is essential in the coordination of both the innate and 
adaptive immune responses 44. 
Overly simplified view of the functionally balanced di-
vision of CD4(+) T cells into Th1 and Th2 lymphocytes re-
mains useful and remains a model of MS pathogenesis 45, 46. 
However, exceptions to Th1-driven MS model may be much 
more prominent, often plentiful, clonal expansion of 
CD8+/MHC class I-restricted T lymphocytes, especially in 
active lesions, whereas the CD4+ phenotype predominates in 
the perivascular space 47. Current data suggest that MS is 
driven by Th1 and Th17 subsets, although they are 
mechanistically different from each other 38, 48. Various pat-
hological, experimental, clinical and immunological findings 
also collectively indicate a pathogenic role of antibodies in 
MS. Serum autoantibodies that targeted extracellular MOG, 
the outermost lamellae of the myelin sheath and hence easily 
accessible to antibody attack, in its native structure were 
shown to be lytic in vitro, supporting a potential pathogenic 
role of these antibodies in MS 49. EAE is the most extensi-
vely studied mouse model of MS 50 and MOG induced EAE 
more closely resembles MS than other EAE variants in 
which inflammation greatly predominates over demyeli-
nation 51. More work is however required to learn the patho-
genic details of the demyelinating events observed in the 
CNS caused by antibodies reactive with myelin constituents 
in EAE and to determine whether these mechanisms are in-
dicative in MS. 
Influenza infection or vaccination as probable  
trigger of MS 
MS is the most common chronic neurological disease in 
young adults, affecting about 2.5 million people wor-
ldwide 52. It is now generally acknowledged that the etiology 
of autoimmune diseases, even though still not clear, includes 
the genetic, immunological, hormonal and environmental 
factors skewing the immune response towards autoreacti-
vity 53. Environmental factors, especially infections, are con-
sidered to be probable, although usually not sufficient, trig-
gers of autoimmune response and can elicit or exacerbate 
autoimmune diseases 54, 24. More recent studies divulge that 
peripheral B-cell responses are closely involved in the im-
mune pathology of MS through proinflammatory mecha-
nisms, bystander activation, or through regulatory functions 
55. It is proposed that aberrant proinflammatory cytokine re-
sponses exhibited by episodically triggered B cells of MS pa-
tients mediate bystander activation of disease-related 
proinflammatory T cells resulting in relapsing disease 
activity 56. Since abnormal cell-mediated and humoral 
immunity play a role in the pathogenesis of disease, a higher 
susceptibility to infections in MS patients is therefore ex-
pected. Although the unbalanced immune system is evident 
in patients with MS, immune defense against common viral 
and bacterial infections appears to be preserved. The infec-
tion rate of commonly occurring infectious diseases is not 
increased among MS patients 57, 58. Additionally, several re-
ports suggested that virus infections could trigger a relapse 
typically observed in relapse-remitting (RR) form of the MS 
patients 59. A possible explanation for disease exacerbation 
after influenza infection could be loss of down-regulation 
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within DC clusters and consequent increase of activated 
cells 60. Therefore, immunization is considered important for 
the MS patients not only to prevent an infectious ailment, but 
also to potentially prevent the MS relapses. The debate about 
vaccine safety in patients with MS is still wide open 61. Cli-
nical onset and the MS disease activity after vaccination ha-
ve been reported 57, 62, 63. 
Hepatitis-B vaccine has been of particular concern and 
most extensively studied in connection with the MS onset. 
The focus on this vaccine followed case reports, in France 
and the US, of the CNS demyelization that have been docu-
mented days to weeks post-vaccination 64. A number of epi-
demiological studies and medical records-based investigati-
ons of hepatitis B vaccine and MS followed these case re-
ports and most of these have shown neither increased risk of 
experiencing a demyelinating episode nor occurrence of MS 
for vaccinated vs unvaccinated individuals 65–67. Studies that 
did show the relationship between hepatitis B vaccine and 
increased risk of MS noted that this vaccine does not repre-
sent a widespread risk factor for the disease 68–71. In 2002, the 
National Academy of Sciences' Institute of Medicine, after 
having examined the published, peer-reviewed scientific and 
medical literature, concluded the lack of association between 
hepatitis B vaccination and the CNS demyelinating disease 
72. Additionally, studies that have examined the potential ef-
fect of hepatitis B vaccination on relapses in people diagno-
sed with  the MS disease could not demonstrate an increased 
risk of relapse 73, 74.  
Other vaccines with potential implications for the MS 
patients that were studied include influenza, because of its 
widespread use, tetanus and measles vaccines. There is no 
definite increase of either occurrence of MS or the risk of 
triggering the MS bouts following the influenza vaccination 
that has been reported. 
Vaccination has proved effective in neutralizing infec-
tious agents by inducing strain-specific antibodies 14. Back in 
1962 Sibley and Foley 57 observed 24 patients with MS fol-
lowing the administration of influenza vaccine. The quadri-
valent inactivated-virus vaccine contained three type A stra-
ins and one type B strain. Antibodies to all four viral strains 
were determined in the MS patients and control patients with 
other neurological disease. The vaccine was well tolerated in 
the group of patients with MS with no convincing evidence 
of adverse reactions to vaccine. Antibody response to influ-
enza vaccination in both groups showed that immunologic 
responsiveness was similar, with usual rise in titer by an ave-
rage of twofold to fourfold after vaccination. In a clinical 
study done by Moriabadi et al. 75 “Influenza vaccination in 
MS” mean antibody response against influenza A virus was 
increased in both MS patients and healthy controls after 2 
weeks post immunization. He also argues against a general 
immune stimulation by influenza vaccination since no incre-
ase of myelin protein–reactive T-cells was observed after 
immunization. The overall data presented in this study sup-
port the effectiveness and safety of influenza vaccination in 
the patients with MS. Our group was reported that anti-
influenza antibody titers in healthy vaccinated mice and in 
MOG induced EAE-vaccinated mice, 4 weeks after vaccina-
tion with inactivated influenza vaccine (split virion), was 
significantly higher compared to the unvaccinated control 
groups, indicating long-lasting antibody response as well as 
preserved immune response in MOG induced EAE mice 76. 
A possible role of several viruses, including influenza A vi-
rus, was investigated in a case-control study in 152 children 
with MS and a significantly higher concentration of antibo-
dies was found in the MS patients comparing with controls. 
This study pointed out more to a complex infectious bac-
kground of MS rather than, ‘a specific virus causes a specific 
disease’ 77. 
Analyzed medical records, which included influenza 
vaccine among other vaccines found no association between 
influenza vaccine and increased risk of MS 67, 71. The studies 
that analyzed whether influenza vaccination affected the risk 
of the MS exacerbation or disability progression demonstra-
ted no relation between influenza vaccine and subsequent 
flare of the disease 78. 
Apart from a risk of MS or the MS relapse from vacci-
nation in general, a few studies investigated the issue of vac-
cine efficacy in the MS patients due to immune system 
dysfunction in genetically predisposed persons, and found no 
sufficient evidence to make a determination 79, 80. The 
antibody levels following various virus vaccination were 
present at similar levels in both MS patients and healthy su-
bjects 81. This suggests that vaccination is likely as effective 
in the MS patients as in the healthy subjects.  
There is a long-lasting concern that a mechanism by 
which immunization may trigger the MS activity may be 
shared among other autoimmune diseases such as GBS. In 
theory, intensified immune response against live attenuated 
viruses (e.g. measles and varicella), inactive viruses (e.g. se-
asonal influenza and hepatitis A), or portions of viruses or 
bacteria [e.g., hepatitis B, human papiloma virus (HPV), and 
pneumococcus] vaccines, that have been included among the 
environmental factors, might also induce an aberrant immune 
response against self-antigens 82. Many common infections 
are known to induce a transient rise in autoantibody produc-
tion. A similar rise in autoantibody production has been ob-
served after various vaccinations. Recently, our group has 
detected a significant increase of anti-MOG antibodies in se-
ra of MOG induced EAE mice and MOG induced EAE-
influenza vaccine vaccinated mice, compared to influenza 
vaccine vaccinated and intact groups. No difference was fo-
und between influenza vaccine vaccinated vs intact groups 
and a positive correlation was found between anti-MOG 
antibody titer and the development of the EAE clinical signs. 
The overall data presented in this study indicate that influen-
za vaccine has no effect on production of autoantibodies and 
development of clinical signs 76. A number of cohort studies 
demonstrated a transient change in autoantibody production, 
with presumably no clinical significance, after influenza vac-
cination in apparently healthy participants 83, 84. These auto-
antibodies usually resolve within a period of 2 months 85 but 
can persist in rare cases. Based on several reported studies, 
the post-vaccination stimulation of autoantibody production 
became one of the criteria of establishing vaccine safety. 
Although autoantibodies have the potential of pathogenicity 
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in several diseases it is often not clear whether they mirror 
events of certain antigens important in the development of 
the illness or represent the causal factor 21. As of now, howe-
ver, the pathological relevance of antibody-mediated auto-
immune encephalomyelitis in MS remains unclear regardless 
their significant deposits in some demyelinating MS lesions 
86. A recent case report done by Amano et al. 87 supported the 
view that anti-MOG antibodies were linked to longitudinally 
extensive transverse myelitis (LETM) established after influ-
enza infection. LETM, defined as a spinal cord lesion that 
extends over three or more vertebrae, is classically associa-
ted with neuromyelitis optica. Spinal cord lesions may, ho-
wever, arise from a number of autoimmune and inflam-
matory diseases that involve the CNS such as MS, sarcoido-
sis or Sjögren syndrome or infectious diseases with the CNS 
involvement 88. The clinical significance of anti-MOG anti-
bodies for diagnosis, treatment, and prognosis has yet to be 
ascertained. Although autoantibodies against MOG are found 
in the clinical spectrum of MOG associated diseases in hu-
mans as well as in different experimental models, the role of 
anti-MOG antibodies in pathogenesis is still unclear 88.  
The mechanism of host response applies equally to an 
infectious invasion and to vaccination 89. However, the pat-
hogenic mechanism underlying the association between viru-
ses and MS is still uncertain. Since vaccinations prime the 
immune system and immune factors are viewed as major 
players in MS, it is plausible that vaccines might work as the 
infections do and molecular mimicry, which is immunologic 
similarity between antigenic determinants of the infectious 
agent or an antigen in a vaccine and an autoantigen, such as a 
myelin peptide in MS, remains the most appealing hypo-
thetic mechanism by which infections/vaccines may trigger 
autoimmune tissue damage 90, 91. The T cell cross-reactivity 
is a general property of T cell recognition probably needed to 
balance the requirement to recognize non-self antigens and to 
reduce the possibility of loss of self-tolerance. In many cases 
of autoimmunity, it leaves an open question whether cross-
reactivity represents an epiphenomenon or a breakdown in 
the ability of T-cells to distinguish self from non-self anti-
gens through the mechanism of epitope spreading 92, 93. It is 
to be, however, remembered that molecular mimicry usually 
requires several weeks following first exposure to an antigen, 
while a second exposure to the same antigen might elicit a 
response within a shorter period of time 94. Other possible 
mechanisms, including pathways of innate immunity that ha-
ve been offered for explaining vaccine induced 
autoimmunity are: latent viral infection that could possibly 
persist in the target tissue and potentially result in 
demyelination; the potential of induction of autoantibodies 
production and abnormal cytokine production triggered by 
vaccination 95.  
Influenza vaccine impact on spatial learning and 
memory in MS 
MS affects motor, sensory as well as behavioral and 
cognitive functions. In the end, it is worthwhile to consider 
the fact that clinically evident cognitive disorders start early 
in the MS disease 96. Cognitive deficits experience approxi-
mately up to 65% of the MS patients 97. The most common 
cognitive symptoms include deficits in the ability to concen-
trate, mental processing speed, impairment of short-term and 
working memory. Among these cognitive deficits, memory 
dysfunction is especially common 98. What causes memory 
dysfunction in MS is currently unknown, but neuroimaging 
studies show demyelination in the hippocampal (a small re-
gion of the brain that forms part of the limbic system) struc-
tures suggesting that hippocampal pathology is involved re-
gardless of cognitive status 99. The number of demyelinating 
plaques in the corona radiata (a pair of white matter tracts 
adjacent to the body of the lateral ventricle), insula (highly 
important island of cerebral cortex), and hippocampus is 
especially correlated with cognitive impairment 100. A study 
performed by Sacco et al. 101 indicated that gray matter and 
hippocampal atrophy occured in the MS patients with and 
without cognitive deficits 101. Studies in humans and animal 
models have provided evidence that hippocampus plays a 
compelling role in spatial memory; the part of memory with 
an ability to regulate and encode information about the sur-
roundings and to navigate in space 102, 103. Nonetheless, the 
hippocampal involvement in cognitive functions has been 
poorly examined in the MS patients and the underlying 
pathophysiology of cognitive symptoms has yet to be unra-
veled. Further, increasing evidence from EAE model sug-
gests that deficits in hippocampal-dependent learning and 
memory are in correlation with early microglial activation, 
synaptic alterations and neurodegeneration. The studies of 
cognitive deficit in animal model EAE can help understand 
the early molecular and physiologic events in the MS patho-
genesis and they represent a diagnostic tool for an early di-
agnosis of the disease in individuals with familial suscepti-
bility to MS 104.  
Neurological and cognitive effects associated with in-
fluenza infection have been reported throughout history but 
the mechanisms underlying these symptoms remain uncle-
ar 105–107. Most influenza strains, including those responsible 
for pandemics, are considered non-neurotropic, suggesting 
that neurological symptoms possibly following an influenza 
infection are not a result of direct inoculation of virus into 
the CNS areas relevant to cognitive behavior, instead it may 
be due to neuroinflammation induced by peripheral viral in-
fection 108–110. Recent experiments have been designed to in-
vestigate whether peripheral infection with influenza virus 
can impact the brain and behavior and to yield insight for 
preventing inflammation and neuronal damage associated 
with peripheral influenza infection. Altered cognitive beha-
viors accompanied by increased microglial reactivity in the 
hippocampus of influenza infected mice as well as influenza 
induced alterations in hippocampal neuron morphology pro-
vide the first evidence that neuroinflammation and architec-
tural changes to hippocampal neurons may underlie functio-
nal deficits in hippocampal-dependent learning and memory 
during influenza infection as shown in the doctoral thesis 
done by Jurgens 111.  
There is as yet insufficient data concerning the effects 
of influenza vaccination on cognitive function. At one point, 
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the goal of our team was to use a MOG induced EAE model 
to ascertain the effects of influenza vaccine on memory loss 
and locomotor dysfunctions in mice using Morris Water Ma-
ze (MWM) test. MWM is a test of spatial learning for ro-
dents. The basic procedure for the MWM is that the rodent is 
supposed to find a platform, either visible (non-spatial ver-
sion) or invisible (spatial version of the test), to escape the 
water by using various cues 112, 113. Cognitive dysfunction in 
infected mice is related to their inability to efficiently navi-
gate to the relocated platform, which is shown by an increase 
in time and path length to find a new platform 111. Our fin-
dings mainly confirm that there is no effect of influenza split 
vaccination on memory impairment in MOG induced EAE 
mice and no significant influence on hippocampal-dependent 
spatial learning. Additionally, although clinical signs of EAE 
are very subtle, the lesions that have been found in the hip-
pocampal region of the brain could be associated with 
memory dysfunction observed during the course of MWM 
testing 114. Even though the initial studies have demonstrated 
that influenza infection induces deficits in spatial learning 
and memory loss in adult mice at day 7 post infection, con-
flicting data exist regarding the connection between MS and 
other autoimmune illnesses and vaccination 95, 111. 
Conclusion 
The debate as to whether vaccination brings more risk 
or benefit continues to be a speculative one and to date neit-
her the advantage of vaccination has been refuted nor the 
vaccination related autoimmune diseases have been 
irrevocably proved. Nonetheless, the medical community 
contemplates current human vaccines, including influenza 
vaccine, safe and effective for patients with autoimmune di-
seases, and immunization is considered important for these 
patients not only to prevent an infectious ailment, but also to 
potentially prevent relapses. It has become evident that im-
munization per se is not enough for triggering autoimmune 
diseases, and that genetic, immunological and hormonal fac-
tors are equally involved. 
A wide work is still ahead of us due to a lack of a well-
established pathophysiology of the central demyelinating 
events and pathogenetic mechanisms underlying the adverse 
neurological events possibly caused by influenza vaccina-
tion. 
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